Faron, etusivu

releases and publications

Faron presents BEXMAB data at ASH Annual Meeting

Interactions with UK Regulatory Authorities

Positive Phase 2 Interim Results from BEXMAB Trial

Regulatory

Targeting Soluble Clever-1 for Autoimmune Diseases

Shareholders’ Nomination Board

Regulatory

Faron’s Capital Markets Day 2024

Regulatory

Faron announces Capital Markets Day

Grant of options

Insider Transaction Regulatory

Faron 2024 Half-Year Financial Results

Regulatory

FDA Grants Fast Track Designation for Bexmarilimab

Regulatory
PreviousNext
Back to top